Four Key Scientists Behind the Vaccines to Share Virtual Stage at November 10 Event; Katalin Karikó, Ugur Sahin, Özlem Türeci, and Drew Weissman to Receive 2021 William B. Coley Award for Distinguished Research in Basic Immunology; Overdue Opportunity to Understand mRNA’s Origins and Future in Cancer Research
The first patients have enrolled in a platform clinical trial, called REVOLUTION, testing combination immunotherapy in patients with metastatic pancreatic cancer. The study uses an innovative design to test multiple combination therapies in parallel.
CRI's free and live online event for patients and caregivers covering cancer immunotherapy, clinical trials, and cancer care disparities takes place Oct. 7-8, 2021.
CRI’s free virtual event to connect U.S. Hispanic cancer patients and caregivers with leading cancer experts to discuss breakthroughs in immunotherapy, patient successes, and clinical trials, will be held on September 16, 2021, at 2 p.m. ET
New CRI health equity program supports young Black, Hispanic, and Latino scientists in the fields of immunology and immuno-oncology at top academic research institutions
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
Rare and ultra-rare cancers affect around 20,000 people in the United States alone, according to Foundation Medicine, Inc. Immunotherapy research in some of the more common cancers and the identification of biomarkers that can predict patient responses is opening this new approach to cancer treatment up to patients whose cancers currently receive little direct attention.
Cancer is not “one-size-fits-all” and neither are its treatments, especially when it comes to immunotherapy. Learn how CRI is helping more people overcome cancer.